TrialAntimicrobial agents and chemotherapy2017

Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model.

Jacqueline M McBride et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.